Guizhou Bailing Group Pharmaceutical Co Ltd (002424) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has a cash flow conversion efficiency ratio of 0.090x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥294.76 Million ≈ $43.13 Million USD) by net assets (CN¥3.28 Billion ≈ $480.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guizhou Bailing Group Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Guizhou Bailing Group Pharmaceutical Co total liabilities for a breakdown of total debt and financial obligations.
Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guizhou Bailing Group Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
-0.203x |
|
Coursera Inc
NYSE:COUR
|
0.009x |
|
Liquidity Services Inc
NASDAQ:LQDT
|
-0.002x |
|
Cansino Biologics Inc
SHG:688185
|
0.006x |
|
Hunan New Wellful Co Ltd
SHG:600975
|
0.064x |
|
Lindblad Expeditions Holdings Inc
NASDAQ:LIND
|
-0.152x |
|
Caisse Régionale de Crédit Agricole Mutuel de Paris et d-Ile-de-France
PA:CAF
|
0.006x |
|
Piedmont Office Realty Trust Inc
NYSE:PDM
|
0.040x |
Annual Cash Flow Conversion Efficiency for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual cash flow conversion efficiency of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Guizhou Bailing Group Pharmaceutical Co stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.20 Billion ≈ $468.14 Million |
CN¥9.02 Million ≈ $1.32 Million |
0.003x | -92.09% |
| 2023-12-31 | CN¥3.53 Billion ≈ $516.15 Million |
CN¥125.77 Million ≈ $18.40 Million |
0.036x | -71.62% |
| 2022-12-31 | CN¥4.00 Billion ≈ $584.87 Million |
CN¥502.15 Million ≈ $73.48 Million |
0.126x | +53.13% |
| 2021-12-31 | CN¥3.96 Billion ≈ $579.50 Million |
CN¥324.92 Million ≈ $47.55 Million |
0.082x | +38.77% |
| 2020-12-31 | CN¥3.92 Billion ≈ $573.66 Million |
CN¥231.78 Million ≈ $33.92 Million |
0.059x | -47.68% |
| 2019-12-31 | CN¥4.14 Billion ≈ $605.25 Million |
CN¥467.41 Million ≈ $68.40 Million |
0.113x | +381.70% |
| 2018-12-31 | CN¥3.92 Billion ≈ $574.31 Million |
CN¥-157.45 Million ≈ $-23.04 Million |
-0.040x | -274.11% |
| 2017-12-31 | CN¥3.47 Billion ≈ $507.36 Million |
CN¥79.88 Million ≈ $11.69 Million |
0.023x | -84.86% |
| 2016-12-31 | CN¥3.07 Billion ≈ $448.56 Million |
CN¥466.62 Million ≈ $68.28 Million |
0.152x | -1.24% |
| 2015-12-31 | CN¥2.68 Billion ≈ $392.31 Million |
CN¥413.23 Million ≈ $60.47 Million |
0.154x | -8.57% |
| 2014-12-31 | CN¥2.35 Billion ≈ $343.57 Million |
CN¥395.83 Million ≈ $57.92 Million |
0.169x | +153.01% |
| 2013-12-31 | CN¥2.13 Billion ≈ $311.30 Million |
CN¥141.76 Million ≈ $20.74 Million |
0.067x | +597.39% |
| 2012-12-31 | CN¥2.04 Billion ≈ $298.89 Million |
CN¥19.52 Million ≈ $2.86 Million |
0.010x | -90.82% |
| 2011-12-31 | CN¥1.94 Billion ≈ $283.94 Million |
CN¥201.90 Million ≈ $29.54 Million |
0.104x | +142.93% |
| 2010-12-31 | CN¥1.85 Billion ≈ $270.28 Million |
CN¥-447.68 Million ≈ $-65.51 Million |
-0.242x | -172.42% |
| 2009-12-31 | CN¥374.42 Million ≈ $54.79 Million |
CN¥125.31 Million ≈ $18.34 Million |
0.335x | +317.54% |
| 2008-12-31 | CN¥262.75 Million ≈ $38.45 Million |
CN¥-40.42 Million ≈ $-5.92 Million |
-0.154x | +64.59% |
| 2007-12-31 | CN¥182.68 Million ≈ $26.73 Million |
CN¥-79.37 Million ≈ $-11.61 Million |
-0.434x | -- |
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more